688382 益方生物
已收盘 03-31 15:00:00
资讯
新帖
简况
每周股票复盘：益方生物（688382）D-2570完成银屑病III期入组
证券之星 · 03-29
每周股票复盘：益方生物（688382）D-2570完成银屑病III期入组
益方生物(688382.SH)终止实施2025年限制性股票激励计划
智通财经 · 03-27
益方生物(688382.SH)终止实施2025年限制性股票激励计划
益方生物(688382.SH)：D-2570治疗银屑病注册性III期临床试验完成全部受试者入组
智通财经 · 03-26
益方生物(688382.SH)：D-2570治疗银屑病注册性III期临床试验完成全部受试者入组
3月23日益方生物跌5.20%，长城医药产业精选混合发起式A基金重仓该股
证券之星 · 03-23
3月23日益方生物跌5.20%，长城医药产业精选混合发起式A基金重仓该股
股市必读：益方生物（688382）今年截至3月20日累计跌幅已超35%
证券之星 · 03-23
股市必读：益方生物（688382）今年截至3月20日累计跌幅已超35%
每周股票复盘：益方生物（688382）D-2570获FDA批准开展银屑病II期临床
证券之星 · 03-22
每周股票复盘：益方生物（688382）D-2570获FDA批准开展银屑病II期临床
管线研发“烧钱”不止，益方生物赴港上市“补血”
市场资讯 · 03-19
管线研发“烧钱”不止，益方生物赴港上市“补血”
益方生物(688382.SH)：D-2570在美国获准开展银屑病II期临床试验
智通财经 · 03-18
益方生物(688382.SH)：D-2570在美国获准开展银屑病II期临床试验
【机构调研记录】嘉实基金调研益方生物、思特威等3只个股（附名单）
证券之星 · 03-16
【机构调研记录】嘉实基金调研益方生物、思特威等3只个股（附名单）
【机构调研记录】南方基金调研三友化工、益方生物等4只个股（附名单）
证券之星 · 03-16
【机构调研记录】南方基金调研三友化工、益方生物等4只个股（附名单）
3月13日益方生物跌6.20%，长城医药产业精选混合发起式A基金重仓该股
证券之星 · 03-13
3月13日益方生物跌6.20%，长城医药产业精选混合发起式A基金重仓该股
3月11日益方生物跌5.71%，长城医药产业精选混合发起式A基金重仓该股
证券之星 · 03-11
3月11日益方生物跌5.71%，长城医药产业精选混合发起式A基金重仓该股
3月6日益方生物涨7.11%，长城医药产业精选混合发起式A基金重仓该股
中金财经 · 03-06
3月6日益方生物涨7.11%，长城医药产业精选混合发起式A基金重仓该股
益方生物赴港上市 商业化稳定性待考
经济参考报 · 03-04
益方生物赴港上市 商业化稳定性待考
股市必读：益方生物（688382）今年截至3月3日累计跌幅已超25%
证券之星 · 03-04
股市必读：益方生物（688382）今年截至3月3日累计跌幅已超25%
每周股票复盘：益方生物（688382）净利亏损3.168亿元
证券之星 · 03-01
每周股票复盘：益方生物（688382）净利亏损3.168亿元
益方生物发布2025年度业绩快报，亏损3.168亿元
证券之星 · 02-26
益方生物发布2025年度业绩快报，亏损3.168亿元
益方生物（688382）披露调整募投项目内部投资结构公告，2月24日股价下跌1.32%
证券之星 · 02-24
益方生物（688382）披露调整募投项目内部投资结构公告，2月24日股价下跌1.32%
益方生物-U(688382.SH）赴港上市新进展：证监会要求补充三项材料
中金财经 · 02-09
益方生物-U(688382.SH）赴港上市新进展：证监会要求补充三项材料
2月2日益方生物跌9.00%，长城医药产业精选混合发起式A基金重仓该股
证券之星 · 02-02
2月2日益方生物跌9.00%，长城医药产业精选混合发起式A基金重仓该股
加载更多
公司概况
公司名称：
益方生物科技(上海)股份有限公司
所属行业：
医药制造业
上市日期：
2022-07-25
主营业务：
益方生物科技(上海)股份有限公司的主营业务是创新药物的研发、生产和销售。公司的主要产品是对外授权产品贝福替尼、对外授权产品格索雷塞、临床试验阶段产品Taragarestrant、临床试验阶段产品D-0120、临床试验阶段产品D-2570。
发行价格：
18.12
{"stockData":{"symbol":"688382","market":"SH","secType":"STK","nameCN":"益方生物","latestPrice":19.02,"timestamp":1774940400000,"preClose":19.52,"halted":0,"volume":10814849,"delay":0,"changeRate":-0.0256,"floatShares":578000000,"shares":578000000,"eps":-0.2011,"marketStatus":"已收盘","change":-0.5,"latestTime":"03-31 15:00:00","open":19.38,"high":19.9,"low":18.94,"amount":209000000,"amplitude":0.0492,"askPrice":19.03,"askSize":27,"bidPrice":19.02,"bidSize":169,"shortable":0,"etf":0,"ttmEps":-0.2011,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1775007000000},"marketStatusCode":5,"adr":0,"adjPreClose":19.52,"symbolType":"stock_kcb","openAndCloseTimeList":[[1774920600000,1774927800000],[1774933200000,1774940400000]],"highLimit":21.47,"lowLimit":17.57,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":578348491,"isCdr":false,"pbRate":6.61,"roa":"--","roe":"--","epsLYR":-0.4167,"committee":0.718901,"marketValue":11000000000,"turnoverRate":0.0187,"status":1,"afterMarket":{"amount":0,"volume":0,"close":19.02,"buyVolume":0,"sellVolume":0,"time":1774942437558,"indexStatus":"已收盘 03-31 15:30:00","preClose":19.52},"floatMarketCap":11000000000},"requestUrl":"/m/hq/s/688382","defaultTab":"news","newsList":[{"id":"2623096387","title":"每周股票复盘：益方生物（688382）D-2570完成银屑病III期入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2623096387","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623096387?lang=zh_cn&edition=full","pubTime":"2026-03-29 01:38","pubTimestamp":1774719490,"startTime":"0","endTime":"0","summary":"截至2026年3月27日收盘，益方生物报收于19.99元，较上周的17.68元上涨13.07%。本周关注点来自公司公告汇总：D-2570治疗银屑病注册性III期临床试验完成全部受试者入组。来自公司公告汇总：益方生物终止2025年限制性股票激励计划，因市场环境及股价波动影响。公司公告汇总益方生物自愿披露，其自主研发的TYK2抑制剂D-2570用于治疗中重度斑块状银屑病的注册性III期临床试验已完成全部受试者入组。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032900000209.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688382","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622845605","title":"益方生物(688382.SH)终止实施2025年限制性股票激励计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2622845605","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622845605?lang=zh_cn&edition=full","pubTime":"2026-03-27 15:38","pubTimestamp":1774597130,"startTime":"0","endTime":"0","summary":"智通财经APP讯，益方生物(688382.SH)发布公告，鉴于当前宏观环境、资本市场以及二级市场价格波动等多方面影响，若继续实施2025年限制性股票激励计划，将难以达到预期的激励目的和激励效果。经公司董事会审慎研究，公司拟终止实施《益方生物科技(上海)股份有限公司2025年限制性股票激励计划(草案)》，与之配套的《益方生物科技(上海)股份有限公司2025年限制性股票激励计划实施考核管理办法》等相关文件一并终止。后续公司将根据外部市场环境适时推出更符合公司发展战略和经营目标的、能有效将股东、公司和员工的中长期利益相结合的激励计划。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1420349.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688382"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622830947","title":"益方生物(688382.SH)：D-2570治疗银屑病注册性III期临床试验完成全部受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2622830947","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622830947?lang=zh_cn&edition=full","pubTime":"2026-03-26 16:48","pubTimestamp":1774514885,"startTime":"0","endTime":"0","summary":"智通财经APP讯，益方生物(688382.SH)公告，公司自主研发的TYK2抑制剂D-2570用于治疗中重度斑块状银屑病(PsO)的注册性III期临床试验已于近日完成全部受试者入组。公告显示，D-2570是公司自主研发的一款靶向酪氨酸激酶2(TYK2)的新型口服选择性抑制剂，用于治疗银屑病等自身免疫性疾病。D-2570通过选择性结合TYK2假激酶域JH2部位，抑制TYK2激酶的活性，进而阻断TYK2依赖性的细胞因子信号传导介导的STAT蛋白的磷酸化，抑制炎症因子释放，参与免疫调节。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419477.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688382","BK4134","BK0239","III"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621768627","title":"3月23日益方生物跌5.20%，长城医药产业精选混合发起式A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2621768627","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621768627?lang=zh_cn&edition=full","pubTime":"2026-03-23 16:39","pubTimestamp":1774255171,"startTime":"0","endTime":"0","summary":"证券之星消息，3月23日益方生物跌5.20%创60日新低，收盘报16.76元，换手率2.6%，成交量15.04万手，成交额2.58亿元。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共70家，其中持有数量最多的公募基金为长城基金的长城医药产业精选混合发起式A。长城医药产业精选混合发起式A目前规模为3.87亿元，最新净值1.5877，较上一交易日下跌1.19%，近一年上涨33.48%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032300025361.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688382","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621745766","title":"股市必读：益方生物（688382）今年截至3月20日累计跌幅已超35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2621745766","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621745766?lang=zh_cn&edition=full","pubTime":"2026-03-23 02:43","pubTimestamp":1774204989,"startTime":"0","endTime":"0","summary":"截至2026年3月20日收盘，益方生物报收于17.68元，下跌3.86%，换手率2.65%，成交量15.32万手，成交额2.78亿元。当日关注点来自交易信息汇总：益方生物股价连续4日下跌，年内累计跌幅达35.08%。该股已连续4日下跌，当年累计跌幅35.08%。资金流向3月20日主力资金净流出954.05万元，占总成交额3.44%；游资资金净流出2379.21万元，占总成交额8.57%；散户资金净流入3333.26万元，占总成交额12.0%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032300000908.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688382"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621796086","title":"每周股票复盘：益方生物（688382）D-2570获FDA批准开展银屑病II期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2621796086","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621796086?lang=zh_cn&edition=full","pubTime":"2026-03-22 02:27","pubTimestamp":1774117630,"startTime":"0","endTime":"0","summary":"截至2026年3月20日收盘，益方生物报收于17.68元，较上周的18.91元下跌6.5%。本周，益方生物3月17日盘中最高价报20.38元。本周关注点公司公告汇总：D-2570获美国FDA批准开展银屑病II期临床试验。目前，D-2570在溃疡性结肠炎、银屑病关节炎、系统性红斑狼疮等适应症的临床试验持续推进中。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032200000594.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688382","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620248572","title":"管线研发“烧钱”不止，益方生物赴港上市“补血”","url":"https://stock-news.laohu8.com/highlight/detail?id=2620248572","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620248572?lang=zh_cn&edition=full","pubTime":"2026-03-19 16:21","pubTimestamp":1773908460,"startTime":"0","endTime":"0","summary":" 作为专注肿瘤、代谢及自身免疫疾病的研发型创新药企，益方生物已成功推出贝福替尼、格索雷塞两款上市并纳入医保的核心产品。 在持续研发投入与现金流不断消耗的双重压力下，为保障D-0502、D-2570等核心管线顺利推进临床，益方生物启动港股IPO寻求资本补充。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/roll/2026-03-19/doc-inhrpfxy1531013.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688382","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620980239","title":"益方生物(688382.SH)：D-2570在美国获准开展银屑病II期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2620980239","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620980239?lang=zh_cn&edition=full","pubTime":"2026-03-18 17:23","pubTimestamp":1773825820,"startTime":"0","endTime":"0","summary":"智通财经APP讯，益方生物 发布公告，公司向美国食品药品监督管理局提交的关于D-2570单药治疗银屑病的II期临床试验申请已于近日到达30天默认期，未收到FDA的反对意见。根据相关规定，D-2570在美国单药治疗PsO的II期临床试验已正式获得批准。此前，公司已完成了在中国开展的D-2570针对银屑病的II期临床试验，研究结果显示，与安慰剂组相比，治疗第12周时，D-2570在皮损清除及疾病严重程度改善方面表现出显著疗效，整体安全性与耐受性良好。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1415451.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"益方生物(688382.SH)：D-2570在美国获准开展银屑病II期临床试验","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688382"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619618481","title":"【机构调研记录】嘉实基金调研益方生物、思特威等3只个股（附名单）","url":"https://stock-news.laohu8.com/highlight/detail?id=2619618481","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619618481?lang=zh_cn&edition=full","pubTime":"2026-03-16 08:01","pubTimestamp":1773619294,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及3月13日披露的机构调研信息，嘉实基金近期对3家上市公司进行了调研，相关名单如下：1）益方生物 调研纪要：D-2570针对中、重度活动性溃疡性结肠炎的II期临床试验已于2025年5月完成首例患者给药，银屑病III期临床试验正按计划推进。2）思特威 调研纪要：2025年公司实现营业收入90.31亿元，较上年同比增加51.32%；归母净利润达10.01亿元，同比增长154.97%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031600001648.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0231","688213","BK0214","688382","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619481634","title":"【机构调研记录】南方基金调研三友化工、益方生物等4只个股（附名单）","url":"https://stock-news.laohu8.com/highlight/detail?id=2619481634","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619481634?lang=zh_cn&edition=full","pubTime":"2026-03-16 08:01","pubTimestamp":1773619293,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及3月13日披露的机构调研信息，南方基金近期对4家上市公司进行了调研，相关名单如下：1）三友化工 调研纪要：公司主导产品开工率约九成，库存低位运行。控股股东表示无减持计划，解禁为正常流通安排，相关承诺仍在履行中。4）普蕊斯 调研纪要：2025年，中国药物临床试验数量达5,173项，同比增长6.44%；1类创新药获批76个，同比增长58%；创新药对外授权交易总金额超1,300亿美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031600001644.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0185","BK0028","BK0196","688382","BK0239","BK0229","BK0188","600409"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619162395","title":"3月13日益方生物跌6.20%，长城医药产业精选混合发起式A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2619162395","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619162395?lang=zh_cn&edition=full","pubTime":"2026-03-13 16:22","pubTimestamp":1773390156,"startTime":"0","endTime":"0","summary":"证券之星消息，3月13日益方生物跌6.20%创60日新低，收盘报18.91元，换手率3.61%，成交量20.88万手，成交额4.0亿元。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共70家，其中持有数量最多的公募基金为长城基金的长城医药产业精选混合发起式A。长城医药产业精选混合发起式A目前规模为3.87亿元，最新净值1.5673，较上一交易日下跌2.94%，近一年上涨39.07%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031300027075.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688382","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618912874","title":"3月11日益方生物跌5.71%，长城医药产业精选混合发起式A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2618912874","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618912874?lang=zh_cn&edition=full","pubTime":"2026-03-11 16:20","pubTimestamp":1773217234,"startTime":"0","endTime":"0","summary":"证券之星消息，3月11日益方生物跌5.71%，收盘报21.15元，换手率2.42%，成交量14.01万手，成交额3.0亿元。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共70家，其中持有数量最多的公募基金为长城基金的长城医药产业精选混合发起式A。长城医药产业精选混合发起式A目前规模为3.87亿元，最新净值1.6497，较上一交易日上涨5.77%，近一年上涨42.56%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031100026229.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688382"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617683786","title":"3月6日益方生物涨7.11%，长城医药产业精选混合发起式A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2617683786","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617683786?lang=zh_cn&edition=full","pubTime":"2026-03-06 16:34","pubTimestamp":1772786058,"startTime":"0","endTime":"0","summary":"证券之星消息，3月6日益方生物涨7.11%，收盘报21.39元，换手率3.52%，成交量20.36万手，成交额4.32亿元。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共70家，其中持有数量最多的公募基金为长城基金的长城医药产业精选混合发起式A。长城医药产业精选混合发起式A目前规模为3.87亿元，最新净值1.5057，较上一交易日上涨2.18%，近一年上涨33.2%。","market":"sh","thumbnail":" http://caiji.3g.cnfol.com/colect/202603/06/20260306506468.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202603/06/20260306506468.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260306/32049957.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["688382","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616500303","title":"益方生物赴港上市 商业化稳定性待考","url":"https://stock-news.laohu8.com/highlight/detail?id=2616500303","media":"经济参考报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616500303?lang=zh_cn&edition=full","pubTime":"2026-03-04 07:59","pubTimestamp":1772582340,"startTime":"0","endTime":"0","summary":"益方生物（688382.SH）近日发布公告，公司已向香港联合交易所有限公司（以下简称“香港联交所”）递交发行H股股票并在香港联交所主板挂牌上市的申请。结合益方生物近年来的业绩表现和账面资 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/20260304/c675054148.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/20260304/c675054148.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["688382","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616373343","title":"股市必读：益方生物（688382）今年截至3月3日累计跌幅已超25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616373343","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616373343?lang=zh_cn&edition=full","pubTime":"2026-03-04 02:22","pubTimestamp":1772562133,"startTime":"0","endTime":"0","summary":"截至2026年3月3日收盘，益方生物报收于19.93元，下跌4.69%，换手率2.54%，成交量14.72万手，成交额2.98亿元。来自交易信息汇总：近90天内3家机构对益方生物给出评级，其中买入评级2家，增持评级1家，机构目标均价为49.25元。交易信息汇总股价提醒3月3日益方生物收盘报19.93元，跌4.69%，当日成交1471.79万元。该股已连续2日下跌，当年累计跌幅26.83%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030400001315.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688382","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616845883","title":"每周股票复盘：益方生物（688382）净利亏损3.168亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2616845883","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616845883?lang=zh_cn&edition=full","pubTime":"2026-03-01 02:30","pubTimestamp":1772303433,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘，益方生物报收于21.34元，较上周的22.01元下跌3.04%。本周，益方生物2月24日盘中最高价报22.33元。本周关注点业绩披露要点：益方生物2025年归属净利润亏损3.168亿元，同比减少31.9%。益方生物科技（上海）股份有限公司预计2025年度实现营业收入3,732.53万元，较上年同期下降77.89%；归属于母公司所有者的净利润为-31,683.84万元，亏损较上年同期扩大。出席会议股东共221人，代表有表决权股份总数218,902,289股，占公司总表决权数的37.8495%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030100000865.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688382"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614301470","title":"益方生物发布2025年度业绩快报，亏损3.168亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2614301470","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614301470?lang=zh_cn&edition=full","pubTime":"2026-02-26 18:21","pubTimestamp":1772101283,"startTime":"0","endTime":"0","summary":"证券之星消息，益方生物近日即将发布2025年年报，根据2月26日发布的业绩快报，归属净利润亏损3.168亿元，同比减少31.9%。基于 2025 年的整体研发进展，公司在报告期内持续保持了高强度的研发投入，公司本期技术授权和技术合作收入尚无法覆盖各项成本及费用，预计 2025年度将继续出现亏损的情况，但公司主营业务、核心竞争力没有发生重大不利变化。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022600030181.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688382","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613879478","title":"益方生物（688382）披露调整募投项目内部投资结构公告，2月24日股价下跌1.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613879478","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613879478?lang=zh_cn&edition=full","pubTime":"2026-02-24 18:01","pubTimestamp":1771927270,"startTime":"0","endTime":"0","summary":"截至2026年2月24日收盘，益方生物报收于21.72元，较前一交易日下跌1.32%，最新总市值为125.62亿元。该股当日开盘22.21元，最高22.33元，最低21.61元，成交额达2.05亿元，换手率为1.63%。近日，益方生物披露《2026年第一次临时股东会会议资料》公告。公司拟调整募投项目“新药研发项目”内部投资结构，新增子项目“YF550”，并调整各子项目间募集资金分配，总投资金额不变。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022400034278.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688382"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610028655","title":"益方生物-U(688382.SH）赴港上市新进展：证监会要求补充三项材料","url":"https://stock-news.laohu8.com/highlight/detail?id=2610028655","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610028655?lang=zh_cn&edition=full","pubTime":"2026-02-09 10:30","pubTimestamp":1770604201,"startTime":"0","endTime":"0","summary":"览富财经网讯：2月6日，中国证监会公布最新一期《境外发行上市备案补充材料要求》，本周国际司共对4家企业出具补充材料要求，其中对在2026年1月1日，向港交所主板递交上市申请书的益方生物科技 股份有限公司，证监会要求其需补充说明三项事项且需律师核查并出具明确的法律意见。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20260209/32006805.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["688382","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608185132","title":"2月2日益方生物跌9.00%，长城医药产业精选混合发起式A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2608185132","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608185132?lang=zh_cn&edition=full","pubTime":"2026-02-02 16:44","pubTimestamp":1770021840,"startTime":"0","endTime":"0","summary":"根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共70家，其中持有数量最多的公募基金为长城基金的长城医药产业精选混合发起式A。长城医药产业精选混合发起式A目前规模为3.87亿元，最新净值1.6587，较上一交易日下跌0.32%，近一年上涨77.44%。梁福睿在任的基金产品包括:长城港股医疗保健精选混合发起A，管理时间为2025年8月20日至今，期间收益率为-17.11%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200023480.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688382","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1774993642627,"stockEarnings":[{"period":"1week","weight":0.0963},{"period":"1month","weight":-0.1087},{"period":"3month","weight":-0.3018},{"period":"6month","weight":-0.3886},{"period":"1year","weight":-0.0037},{"period":"ytd","weight":-0.3018}],"compareEarnings":[{"period":"1week","weight":0.0027},{"period":"1month","weight":-0.0651},{"period":"3month","weight":-0.0194},{"period":"6month","weight":0.0023},{"period":"1year","weight":0.1667},{"period":"ytd","weight":-0.0194}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"益方生物科技(上海)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"12352人(较上一季度增加26.17%)","perCapita":"46822股","listingDate":"2022-07-25","address":"上海市浦东新区中国(上海)自由贸易试验区李冰路67弄4号210室","registeredCapital":"57834万元","survey":" 益方生物科技(上海)股份有限公司的主营业务是创新药物的研发、生产和销售。公司的主要产品是对外授权产品贝福替尼、对外授权产品格索雷塞、临床试验阶段产品Taragarestrant、临床试验阶段产品D-0120、临床试验阶段产品D-2570。","listedPrice":18.12},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"益方生物(688382)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供益方生物(688382)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"益方生物,688382,益方生物股票,益方生物股票老虎,益方生物股票老虎国际,益方生物行情,益方生物股票行情,益方生物股价,益方生物股市,益方生物股票价格,益方生物股票交易,益方生物股票购买,益方生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"益方生物(688382)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供益方生物(688382)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}